CRISPR Therapeutics Analyst Ratings
Adaptive Biotechnologies Analyst Ratings
Veracyte Presents New Data Findings Are From The Prospective, Multicenter VANDAAM Trial, Show That Its Decipher Prostate Test Predicts Aggressive Prostate Cancer In African American Men At ASTRO 2024
Unveiling 3 Analyst Insights On Arcturus Therapeutics
Twist Bioscience Analyst Ratings
Cassava Sciences Stock Sinks 14% After $40 Million Settlement With SEC
10x Genomics Short Call Reiterated at Hedgeye, Sees Potential for 50% Downside
Jabil Posts Upbeat Earnings, Joins Micron Technology, Southwest Airlines And Other Big Stocks Moving Higher On Thursday
12 Health Care Stocks Moving In Thursday's Intraday Session
Crude Oil Down Over 2%; US Initial Jobless Claims Fall
Ionis Pharmaceuticals Analyst Ratings
Pfizer Withdraws Sickle Cell Drug Oxbryta Over Safety Concerns
Reported Earlier Intellia Therapeutics To Present Data From The Phase 2 Study Of NTLA-2002 For The Treatment Of Hereditary Angioedema At The 2024 ACAAI Annual Scientific Meeting; To Host Investor Webcast On October 28, At 8:00 A.m. ET
Small-cap Stocks Have Climbed Recently. Here Are the Ones Most Poised for Further Upside
Looking Into Recursion Pharmaceuticals's Recent Short Interest
Coeur Mining, Medical Properties Trust And RH Are Among Top 7 Mid Cap Stock Gainers Last Week (Sep 8-Sep 14): Are The Others In Your Portfolio?
Stock Moves Reflect Downgrade for US Economic Growth Outlook - Goldman
CareDx Names Keith Kennedy as COO
Expert Outlook: Intellia Therapeutics Through The Eyes Of 7 Analysts
Intellia Therapeutics Analyst Ratings